ONCAlert | 2018 ASCO Annual Meeting

Questions That Remain Regarding Combination, Sequencing With PARP Inhibitors

Patricia LoRusso, DO, PhD
Published Online: 11:47 PM, Sat September 24, 2016

Patricia LoRusso, DO, PhD, professor of medicine and associate director of Innovative Medicine at Yale Cancer Center, discusses the key questions that still remain regarding combination and sequencing with PARP inhibitors.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.